Flagship peptide evidence profile

Pramlintide

Attributable relationships

Direct human-primary

Direct controlled human

Direct reviews

Direct animal-primary

Primary subject

Comparator

Multi-agent

Class-level

Contextual

Research-gap signals

These are deterministic research-intelligence signals, not clinical conclusions.

No directly attributed human-primary study in the current Flagship review set.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Reviewed evidence

reviewnarrative reviewcontextual mention

Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance.

Pramlintide · PMID 39998445

View structured evidence

reviewnarrative reviewclass level evidence

Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.

Pramlintide · PMID 38338796

View structured evidence

reviewnarrative reviewcontextual mention

Amylin: Pharmacology, Physiology, and Clinical Potential.

Pramlintide · PMID 26071095

View structured evidence

reviewnarrative reviewcontextual mention

The story of amylin: from physiology to therapy.

Pramlintide · PMID 41708975

View structured evidence

systematic review meta analysisreview level evidencesecondary multi agent subject

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.

Pramlintide · PMID 25590213

Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide (2.6 kg), glipizide (2.2 kg), sitagliptin (0.55 kg), and nateglinide (0.3 kg).

View structured evidence

reviewnarrative reviewcontextual mention